Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

NCT04082416 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

335

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Placebo plus standard therapy
BIOLOGICAL: RC18 160 mg plus standard therapy

Sponsor

RemeGen Co., Ltd.